Bully Sanofi is out. I'm not surprised. "Jan. 2018 to date: Mymetics finished the study during Q4 2018 and presented the data to Sanofi. The blinded study incorporated 12 groups of 10 mice which received different virosome formulations, administered through different routes, and one control formulation. The results were positive for most of Mymetics virosome formulations, some virosomes generated significantly higher HA inhibition (HAI) titers and good antibody titers. Although this study was successful and the Company has discussed the results with Sanofi, Mymetics for the time being will not be continuing its collaboration with Sanofi due to other priorities of Sanofi. We are evaluating the possible publication of the results."
https://www.sec.gov/Archives/edgar/data/927761/000165495419003503/mymx_10q.htm

Seems to be the case? Isn't it?

If that's the case, where's the Big Pharmas partnerships?

Very well said HH! Thanks

regards,

ACImmune,SA (Nasdaq:ACIU) is the real deal!
Partners: Genentech/Roche, Janssen,a Johnson&Johnson Co., Biogen, Eli Lilly, Life Molecular Imaging

https://www.acimmune.com/en/pipeline-overview/

Viral Vectors as delivery system is gaining traction!

German firm that serves gene therapy biotechs opens Cambridge HQ

A German company that makes viruses used to deliver gene therapies to patients officially launched its U.S. operations this week with a new headquarters in Cambridge.

Sirion Biotech International, a subsidiary of Sirion Biotech GmbH, opened the headquarters in Alewife on Thursday. The parent company has 30 employees, and the new office currently has five employees.

The company modifies viruses used to ferry therapies for genetic diseases into cells or directly into gene sequences. It works with companies to create their own libraries of viruses that can be used for research, clinical trials or drugs.

Local companies like Biogen, bluebird bio, Intellia Therapeutics and Voyager Therapeutics are leading the charge on gene therapy with potential treatments for sickle cell, vision disorders and other diseases.

The market for gene therapies is projected to reach grow 33 percent annually, reaching $4.4 billion globally by 2023, according to Allied Market Research. With many of its contracts including milestone and other longer-term licensing payments, Sirion is anticipating $50 million in revenue in the next few years, according to Chief Operating Officer Dieter Lingelbach.

"This is opening an avenue to move some decision-making into Cambridge," he told the Business Journal. "We’ve got high regard for how Massachusetts is developing (the gene therapy) industry."

The push for gene therapies has created a logjam in the pursuit of so-called viral vectors. While some companies develop their own viral vectors in-house, many flock to research institutions like UMass Medical School and the University of Pennsylvania or companies like Sirion, North Carolina-based StrideBio, LLC and Maryland-based Regenxbio to license the tools.

The demand for vectors has led to lengthy production delays, Lingelbach said. Some firms ultimately sign vector production contracts with multiple vector companies to dodge the risk of expensive or unsurmountable problems creating the viruses, as was the case with bluebird bird, the New York Times reported in 2017.

Sirion has already gotten off to a busy start in the U.S. Ahead of the opening this week, the German biotech firm signed two major partnerships with Boston-based Orchard Therapeutics (Nasdaq: ORTX) and San Francisco-based Denali Therapeutics (Nasdaq: DNLI), and is also in the process of closing another partnership with a U.S. biotech company focused on hemophilia treatments. It anticipates launching five more partnerships in the next two years and growing the 60 percent of Sirion's business that is already conducted in the U.S.

"Sixty percent is just the tip of the iceberg," Lingelbach said.

https://www.bizjournals.com/boston/news/2019/02/01/german-firm-that-serves-gene-therapy-biotechs.html?ana=yahoo&yptr=yahoo


I wonder the differences between Mymetics' Virosome IPs to theirs?

22nd January 2019 - Successful completion of EU Horizon 2020 Grant MACIVIVA

>>> Written on 06 February 2019.

In 2014, Upperton Pharma Solutions was awarded a prestigious Horizon 2020 grant as part of a European consortium led by Mymetics, a pioneering company at the forefront of the development of virosome-based vaccines.

The MACIVIVA goal was to develop dry powder, thermostable, cold-chain independent virosomal vaccine formulations for non-invasive needle-free administration. Such solid form vaccines should reduce the cost and improve safety and compliance in National Immunisation Programs, particularly in the developing world.

The Upperton formulation development team successfully developed spray dried formulations of HIV virosomal vaccines for both oral and nasal delivery routes. The optimised processes were scaled up and transferred into the company’s GMP clean room facility, where batches of both the Oral and the Nasal formulation were manufactured.

Upperton’s spray dried Virosomal Vaccine formulations:

***Retained virosome structure and particle size on spray drying
***Preserved antigenicity in the final solid vaccine forms
***Retained the initial vaccine immunogenicity after storage for three months at 40°C / 75%RH
***Both nasal and oral formulations were successfully dosed in animal models
***The immunogenicity of the nasal solid vaccine form was comparable to subcutaneous injection of the reference liquid vaccine
Participation in the MACIVIVA project has enabled Upperton to expand their technical capabilities to include GMP manufacture of solid form virosomal vaccines.

http://www.upperton.com/news/59-22nd-january-2019-successful-completion-of-eu-horizon-2020-grant-maciviva

This is great!

regards

So.... They have the same delivery approach of using Dendritic Cells like eTheRNA does. Funny, with all the preparation complexities they're doing with their material, eTheRNA simplified everything by using a messenger RNA (mRNA) to be delivered to the dendritic cells using our virosomes.


Directing the delivery

"Hubbell and his colleagues approached this problem as a delivery issue. To deliver the vaccine to its intended target, they developed a vaccine platform made up of a polymeric adjuvant—which contains multiple adjuvant molecules connected like pearls in a necklace—coupled with an antigen. This platform can easily drain into the secondary lymphoid tissues".

"To make sure it found its way to the intended site, they incorporated mannose, a type of sugar, into the polymeric adjuvant. Because viruses and bacteria tend to have a lot of sugar on their surfaces, the dendritic cells in the lymphoid tissues have several sugar receptors that help in the recognition of pathogens".

"So once the mannose-laden vaccine is injected into the body, it targets specific immune cells called dendritic cells, which in turn activate T cells. By specifically targeting dendritic cells, this new technology prevents systemic inflammation while efficiently activating an immune response".

https://medicalxpress.com/news/2019-02-vaccine-malaria-effective.html

Exclusive: head of Food and Drug Administration’s opioid advisory team says officials are manipulating process to benefit big pharma

FDA's opioids adviser accuses agency of having 'direct' link to crisis

The Food and Drug Administration is sacrificing American lives by continuing to approve new high-strength opioid painkillers, and manipulating the process in favor of big pharma, according to the chair of the agency’s own opioid advisory committee.

Dr Raeford Brown told the Guardian there is “a war” within the FDA as officials in charge of opioid policy have “failed to learn the lessons” of the epidemic that has killed hundreds of thousands of people over the past 20 years and continues to claim about 150 lives a day.

Brown accused the agency of putting the interests of narcotics manufacturers ahead of public health, most recently by approving a “terrible drug”, Dsuvia, in a process he alleged was manipulated.

Read more:https://www.theguardian.com/us-news/2019/jan/24/fda-opioids-big-pharma-prescriptions?CMP=twt_a-world_b-gdnworld

Exactly! However, I heard that their (MRNA) approach of using LNP leads to toxicity issues in the liver. Not really sure how true is this but a possibility.

Came across this: Does Moderna Therapeutics’ pipeline depend upon its patent dispute with Arbutus Biopharma over mRNA delivery?

Moderna is currently embroiled in an intellectual-property dispute that may be material to its long-term profits, regardless of which of the products in its pipeline eventually succeed. This is because its technology relies upon a game-changing approach that harnesses a patient’s own protein-making machinery to essentially manufacture its own therapeutic protein.

But to achieve that, Moderna must deliver mRNA to the patient’s cells. At least one company, Arbutus Biopharma, has already claimed that Moderna’s tech uses its mRNA delivery technology. Two pending patent disputes may decide whether Arbutus’ patents are a roadblock to Moderna’s revenue.

Moderna’s therapeutics focus on designing mRNA for a desired protein, and then delivering that mRNA to the body. This process then relies upon the body to manufacture the desired protein, rather than administering the protein directly, as in the case of biologics.

One hitch in this process is delivering the mRNA to the body’s cells. That can be difficult. One method is through lipid nanoparticles, or LNPs. Moderna previously licensed mRNA delivery technology using LNPs from a small Canadian company called Acuitas. Acuitas had itself acquired a license to this technology from Arbutus Biopharma (which was formerly known as Protiva Biotherapeutics.) Arbutus subsequently claimed that Acuitas’ sublicense to Moderna was improper, and won a preliminary injunction in Canada against Acuitas’ sublicense.

https://www.markmanadvisors.com/blog/2018/12/17/does-moderna-therapeutics-pipeline-depend-upon-its-patent-dispute-with-arbutus-biopharma-over-mrna-delivery

Five Star Post! Thanks HH!

Oooops...my bad- hangover. I meant next week.

So...both Anergis and eTheRNA are presenting this week at SF.

“We are very satisfied with these new results because we now have a strong data base to expect successful clinical development of our second-generation COP Allergy Vaccines,” said Vincent Charlon, CEO of Anergis. “The new presentation of our peptides ensured a boost in immunogenicity without the development of specific IgEs during treatment. This combination should result in greater efficacy and improved tolerability as compared to the first generation. We will be happy to discuss the results in further detail at the upcoming Biotech Showcase / J.P. Morgan Healthcare Conference in San Francisco in January.”
http://www.anergis.ch/news/96-anergis-cop-2018-second-generation.html


On 7 January (at 11:45 am) eTheRNA’s CEO Steven Powell wIll present our #mRNA platform and our clinical program at the #Biotech showcase in #sanfrancisco parallel to #jpmorgan #healthcare conference

On 7 January (at 11:45 am) eTheRNA’s CEO Steven Powell wIll present our #mRNA platform and our clinical program at the #Biotech showcase in #sanfrancisco parallel to #jpmorgan #healthcare conference pic.twitter.com/5dNO1O4Po9

— eTheRNA (@eTheRNA_engine) January 2, 2019

Wishing a Happy & Prosperous New Year to all!


regards,

That info is outdated : Source: Mymetics Corporation on 03/28/2013

This is the period when the "duo" Grant Pickering and Dr. Christopher Henney became the new CEO and Chairman of BOD, respectively.

Just to clarify this matter.

regards,

The Question is:
1. Why did Mymetics give Anergis a time LIMITED option to enter an exclusive licensing agreement?

quote:
Anergis has time limited exclusive option to license Mymetics' virosome technology in the field of allergies

https://finance.yahoo.com/news/mymetics-virosomes-successful-allergy-proof-060000598.html


2. Why did Anergis agree to such term?

quote:
Should Anergis and Mymetics execute a License and Collaboration Agreement (LCA), Anergis would make an upfront payment to Mymetics in an amount that increases as the date of executing the LCA is delayed, milestone payments based on certain regulatory clearances and royalties for net sales.

https://www.sec.gov/Archives/edgar/data/927761/000165495418004222/mymx_8k.htm


~ Is it because there are others in line?
~ Is it because Anergis wanted to seal the deal before Mymetics gets bought?
~ Knowing the background of Anergis' CEO and BOD, will they consider a licensing deal? or M&A?
~ What's SANOFI's interest in Allergy Immunotherapies?

Just thinking out loud (imho)

regards,

GREAT NEWS indeed! Kudos to you for all your FIVE STAR DDs and effort. Thank you!

Now clock is ticking! Anergis better close the licensing deal or somebody watching will. Allergy Immunotherapy market is getting HOT!

regards,

SEC targets proxy and short selling rules, compensation disclosures for possible changes
Published: Nov 27, 2018 5:52 p.m. ET

"There are also several rule reviews requested related to short-selling and rules preventing naked short selling. For example, Regulation M, “Anti-Manipulation Rules Concerning Securities Offerings”, is intended to protect the independent pricing mechanism of the securities market so that IPO offering prices result from “the natural forces of supply and demand” and are not impacted by market manipulation.

One of the rules in this group is concerned with short selling that may artificially depress market prices and lead to lower than anticipated offering prices, reducing the proceeds from the IPO.

Another short-selling related rule on the list created an antifraud provision under federal securities laws to address fraud that occurs when traders associated with “naked” short selling deceive others about their intention or ability to deliver securities in time for settlement and fail to deliver securities by settlement date."

The list is open for public comment, but in general few take advantage of the opportunity. Former SEC commissioner Michael Piwowar noted in 2016 that “historically the lists have generated little or no public comment. In fact, in recent years the annual Rule List has prompted, on average, only one comment.”

https://www.marketwatch.com/story/sec-targets-proxy-and-short-selling-rules-compensation-disclosures-for-possible-changes-2018-11-27?siteid=yhoof2&yptr=yahoo

regards,

HAPPY THANKSGIVING !!!

regards,

AC Immune Awarded Third Follow-up Grant from The Michael J. Fox Foundation for First-in-Human Study of a Positron Emission To...

* Grant supports next step in development of potentially first alpha-synuclein PET tracer for Parkinson's disease
* Start of first-in-human study of current lead is scheduled for Q1 2019
* Follow-up grant marks longstanding collaboration with The Michael J. Fox Foundation (MJFF)

Lausanne, Switzerland, November 15, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced it has been awarded a follow-up grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). In 2015 AC°Immune received a research grant from the MJFF to support the development of a Parkinson's-specific diagnostic agent. Following a grant extension in 2017, the new grant is an acknowledgement of the progress AC Immune has made in this program. This grant aims to facilitate the execution of a first-in-human study for a potential alpha-synuclein PET tracer with the current lead compound. The study will commence in Q1 of 2019. The amount of the grant has not been disclosed.

Prof. Andrea Pfeifer, CEO of AC Immune, said: "We are honored to receive, for the third time, funding from the prestigious Michael J. Fox Foundation underlining our collaboration and dedication to find earlier and more accurate tools for the diagnosis of Parkinson's disease. This new follow-up grant further validates AC°Immune's leading expertise in the pathology of misfolded proteins and our vision to become a global leader in precision medicine of neurodegenerative diseases."

https://ih.advfn.com/p.php?pid=nmona&article=78695919

Hmmmmm....results has been moved to November 2018!

From latest 10-Q (11/13/2018)

"One project with Sanofi for influenza vaccines, for which we are currently conducting a pre-clinical studies and results are expected not before November 2018".

https://www.sec.gov/Archives/edgar/data/927761/000165495418012525/mymx_10q.htm


From previous 10-Q (08/13/2018)

"One project with Sanofi for influenza vaccines, for which we are currently conducting a pre-clinical studies and results are expected not before October 2018".

https://www.sec.gov/Archives/edgar/data/927761/000165495418008862/mymx_10q.htm



On another note: Major shareholders made another cash infusion this month, a continued vote of confidence. "In November, 2018, the Company agreed with Round Enterprises Ltd and Eardley Holding AG the issuance of promissory notes with a total combined value of E800, with an annual interest rate of 2.5% and a maturity date which is the later of (i) June 30, 2019, or (ii) the end of a subsequent calendar quarter in which the Company receives a written request from the lender for repayment of the unpaid principal and accrued interest due under the Notes. The total amount of E800 has been received on November 2018".

https://www.sec.gov/Archives/edgar/data/927761/000165495418012525/mymx_10q.htm


I hope a monumental event for Mymetics is in the works.

regards,

I admit, I was surprise when I watch the video on the potential of this collaboration with Anergis. This is huge!

later bro, heading to work. Appreciate all your effort here, as well as others.

regards,

Great find HH! Thanks for sharing. Seems another catalyst coming before end of this year(2018).

regards,

WOW! 3 consecutive prs recently. This is getting more eyes watching!
Its not a surprise when one day AC Immune will be acquired, in my opinion.

regards

"Phase II Hiv trial won't move this imho"

Huh? I'm thinking the opposite, especially in partnership with big Pharma. We'll see, what happens as a result of the MACIVIVA campaigns going on.

regards,

mRNA has the potential to address a wide range of conditions and cancers

Vaccines have been around for more than 100 years, helping to prevent the spread of dangerous diseases and bring some former killers, like polio, close to global elimination.

“But despite the success of vaccines to prevent disease, there are still significant unmet medical needs. Sanofi is addressing those needs both by significantly improving existing vaccines, as we’ve done for influenza, and looking for new, novel vaccines for serious diseases like RSV.”

“There are several proteins that we need to make for novel vaccines, and unfortunately, some are extremely difficult to produce and formulate into a vaccine,” Jackson said. “Messenger RNA opens the door to these very difficult proteins that we otherwise couldn’t produce and it allows us to pursue targets that we otherwise would not have the tools for.”

Sanofi plans to work rapidly to assess the best potential candidates for mRNA vaccine targets in alignment with its strategic priorities, as it also pursues a wide range of technologies from inside and outside the company’s labs to improve vaccines and public health.

https://www.sanofipasteur.com/en/innovation-and-research/vaccines-for-tomorrow/inoculation-innovation/

Bottom line, an effective delivery system such as Mymetics' VLP is the key to carry these mRNA proteins to a specific target in order to successfully develop an effective mRNA based vaccines. eom

regards,

You're TOTALLY WRONG! based on your lack of understanding of their financials.

"no assets (just goodwill and 1 million of cash that they probably already burned through)",--- AREN'T INTELLECTUAL PROPERTIES (IP), PIPELINE ASSETS???

"no revenues" --- AREN'T GRANTS REVENUES??? If you're referring to sales, DOES A R&D company mean to you??? R&D companies revenues comes from grants and research services conducted.

"61 million in short-term debt"--- Wrong! This are mostly LONG TERM LIABILITIES.


Keep Trying, Good Luck buying shares though.

Thanks much HH! for updating the ibox and your/others' invaluable dds here.

regards,

There's 3 reactions/comments from that article which is attracting heavy traffic of readers and a poster "nito" is one of them referring to Mymetics. Maybe people who read it realized that MACIVIVA is a better approach to needle free vaccination versus the other vaccine mentioned using Sanofi's Fluzone as comparator. Funny coz as "nito" mentioned, Sanofi is already ahead of the game improving Fluzone in collaboration with Mymetics which makes their data irrelevant once Sanofi launch the new generation of Fluzone. lol

https://finance.yahoo.com/news/vaxart-apos-flu-vaccine-superior-143002202.html

Thanks for bringing this up! and kudos to you nito!
I urge everyone especially LONGS here to support and follow up nito's determination to spread the word and Mymetics! There are about 145 views as I just checked it. WOW!!!.

MYMX Long&Strong!

regards,

Today's Presentation:

Vaccines & Infectious Diseases Panel
Chaired by:
Florian Schödel, Owner, Philimmune, LLC
Panelists:
Alexander Kort, SVP, Corporate Development, Themis
Bioscience GmbH
Enza Di Modugno, Director, Global BD, Roche Partnering
Graham Dixon, CEO, Neem Biotech Ltd.
Mark Emalfarb, President & CEO, Dyadic International, Inc.
Rainer Lichtenberger, CEO, ATRIVA Therapeutics GmbH
Ronald Kempers, President & CEO, Mymetics SA

http://www.sachsforum.com/uploads/5/1/9/6/51964431/bef18_final_agenda.pdf

Chaired by:
Florian Schödel, Owner, Philimmune, LLC

Florian is a professional with > 30 years large pharmaceutical, biotech industry and academic experience of leading teams in the development of vaccines and biologics.
His passion is preventative medicine and the use of modern science and technology for the improvement of public health – especially in the development of preventative and therapeutic vaccines and biologics.
As an experienced and successful pharmaceutical executive, he has a track record in running scientific and operational organizations, in business and strategic planning, for forming international strategic partnerships and alliances, in target identification and in all steps of clinical and pre-clinical development.
He has directed the design and execution of clinical studies for licensure and routinely interacts with international and national regulatory agencies.
He has led the clinical teams responsible for several successful vaccine filings.
A physician and microbiologist by training, Florian was a VP in Vaccines Clinical Research of Merck Research Laboratories.
Florian graduated in medicine at the Technical University, Munich, and earned doctorates in Transplantation Immunology and Medical Microbiology (Dr. med. Dr. med. habil.) from the University of Munich (LMU). He holds adjunct faculty appointments at the LMU and at the Biodesign Center of the ASU. Florian’s research at the Max-Planck Institute for Biochemistry, at Scripps, WRAIR and INSERM focused on hepatitis B and on novel recombinant vaccines against diseases such as hepB, malaria and typhoid.
Florian joined MRL in 1996 as Director Clinical Vaccine Research leading EU vaccine clinical trials and the clinical development of rotavirus, measles, mumps and rubella vaccines. As the clinical liaison to an EU joint venture (SP-MSD) he participated in the development of pediatric combination vaccines. He led clinical teams in vaccines and biologics and contributed to clinical and analytical research development.
Specialties:
Vaccines and Biologics Development Strategy, Clinical Development, Vaccines, Clinical Operations, Strategic Planning and Alliances, International Collaborations, Analytical and Assay Development, Project and Portfolio Integration and Leadership

affiliations/clients:
•board of directors
VLP-Biotechnology
•scientific advisory board Variation Biotechnologies
•scientific advisory board (past)
Ancora Pharmaceuticals
•scientific advisory board
Moderna/Valera
•GSK Biologicals
•Intercell AG
•Optinose
•Genocea Biosciences
•PTC Therapeutics
•SGVI
•Takeda Pharmaceuticals
•Enumeral Biomedical
•NovaDigm Therapeutics
•Amgen
•Athersys
•5AM
•PATH
•The Wellcome Foundation
•Sequoia Sciences
•Biogen
•Vaxxilon
•Minervini Ricerche
•CANVAS
•Sanofi
•VaxYnethic
•Biological E

http://philimmune.com/philimmune.macmate.me/Owner.html


regards,

Good read!

How an HIV Trial Triggered a 667% Jump in Australian Penny Stock...

The Sydney-based drug company with just five full-time employees last week announced the “successful” outcome of a phase-two trial of BIT225 HIV-1 drug and retail investors have been lapping it up. The company said its therapy suppressed the HIV virus more than current antiretrovirals.https://finance.yahoo.com/news/hiv-trial-triggered-667-jump-052713187.html

Anytime now Mr. Kempers!

MYMX Long&Strong!

regards,

What's going on? Ask sore in the eyes! Trying to discourage potential buyers? FAKE???

Long&Strong!

regards,

“On the basis of the extensive clinical experience available with virosomes and with Anergis COPs against birch allergy, we are convinced that their combination represents a highly attractive opportunity to develop safe and efficacious ultra-fast COP allergy vaccines” commented Vincent Charlon, CEO of Anergis.
http://www.anergis.ch/news/93-anergis-mymetics-collaboration-180423.html

A very strong, powerful statement particularly on virosomes! Not surprisingly, virosomes has been proven, FDA approved and used as delivery, and/or adjuvant for some vaccines in the market. It's a matter of who's got the best virosomal technology platform and Mymetics is at the forefront in best-in-class new generation virosome-based virus like particles (VLP), in my opinion.

regards,
Long&Strong!

COMPANY OVERVIEW >>> UPDATED!
https://www.mymetics.com/files/5015/3606/2025/180831_Mymetics_Company_Overview_-_website.pdf

regards,

I hope you're right!

GL to Longs!

Bottom line is the OS remained @ 303.7 million since 2014. NO dilution for more than 4 years now. It's a mere mistake of data entry,it happens, no worries.

regards,

It'll be interesting if it happens.

AC Immune Announces Important Clinical Milestones for ACI-24 Vaccine in Alzheimer's Disease and Down Syndrome

* Start of Phase 2 trial with ACI-24 in patients with mild Alzheimer's disease; first patient enrolled
* Recruitment completed for high-dose cohort of Phase 1b study with ACI-24 for Abeta-related cognitive decline in individuals with Down Syndrome

ACI-24 Vaccine for Alzheimer's Disease
AC Immune has started the Phase 2 study with ACI-24 in patients with mild Alzheimer's disease (AD). The aim of this double-blind, randomized, placebo-controlled study with an adaptive design is to assess the safety, tolerability, immunogenicity, target engagement, biomarkers and clinical efficacy of ACI-24. The trial will seek to confirm the positive trends on Abeta PET* imaging and clinical measurement (CDR-SB°) of the previous Phase 1 safety study. The Phase 2 trial will be conducted in several European countries and the first patients have been screened.

ACI-24 in Down Syndrome
AC Immune has completed recruitment for the high-dose cohort of the ACI-24 Phase°1b study for the treatment of Alzheimer's disease-like characteristics in adults with Down Syndrome (DS), a condition affecting approximately one in 700 newborns. The first low-dose and the second high-dose cohorts have been fully recruited in August 2017 and in July 2018 respectively, and interim results of the low dose cohort are expected later in 2018. In addition to cognitive dysfunction beginning in childhood, individuals with DS are genetically-predisposed to develop Abeta-related cognitive decline at a much younger age and with much greater probability than the general population.

http://ir.acimmune.com/phoenix.zhtml?c=254264&p=irol-news&nyo=0

Now posted on website:
22-08-2018
Development of a Virosomal RSV Vaccine Containing 3D-PHAD® Adjuvant: Formulation, Composition, and Long-Term Stability

June 26th, 2018 - Characterization of virosomes, in late stage preclinical development as vaccines for Respiratory Syncytial Virus (RSV), with a membrane-incorporated synthetic monophosphoryl lip....

https://www.mymetics.com/media-center/

Would be nice if they PR this!


regards,